AI can streamline biosimilar adoption by simplifying prescribing decisions and reducing costs.
Josh Canavan
Advertisement
Articles by Josh Canavan
Gaps in education about biosimilars, particularly among pharmacists, patients, and prescribers, are a significant barrier to wider adoption.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
3
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
4
PCV20 Demonstrates Real-World Effectiveness Against Pneumonia in Older Adults
5
